Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
Heinrich K, Stintzing S, Weikersthal LFV, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Jung A, Holch JW, Held S, Modest DP, Heinemann V. Heinrich K, et al. Among authors: modest dp. Eur J Cancer. 2025 Nov 22;232:116133. doi: 10.1016/j.ejca.2025.116133. Online ahead of print. Eur J Cancer. 2025. PMID: 41319450
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
Stahler A, Modest DP, Stintzing S, Borelli B, Keller T, Held S, Fischer von Weikersthal L, Müller L, Graeven U, Decker T, Heintges T, Kahl C, Hoppe B, Kiani A, Kaiser F, Schwaner I, Fruehauf S, Karthaus M, Trarbach T, Klauschen F, Horst D, Cremolini C, Heinemann V. Stahler A, et al. Among authors: modest dp. J Clin Oncol. 2025 Nov 18:JCO2500596. doi: 10.1200/JCO-25-00596. Online ahead of print. J Clin Oncol. 2025. PMID: 41252656
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V. Weiss L, et al. Among authors: modest dp. Eur J Cancer. 2025 Nov 13;232:116105. doi: 10.1016/j.ejca.2025.116105. Online ahead of print. Eur J Cancer. 2025. PMID: 41240527 Free article.
The Prognostic Role of Frailty and Its Recognition With Simple FRAIL and Fried Frailty Questionnaires in Advanced Cancer Patients.
Weinländer P, Hadzibegovic S, Porthun J, Kretzler L, Evertz R, Lena A, Lück LC, Hella JL, Wilkenshoff U, Stroux A, Keramida K, Letsch A, Modest DP, Bullinger L, Keller U, Karakas M, Abdelwahed YS, Attanasio P, Rauch U, Skurk C, Doehner W, Landmesser U, von Haehling S, Anker MS. Weinländer P, et al. Among authors: modest dp. J Cachexia Sarcopenia Muscle. 2025 Oct;16(5):e70076. doi: 10.1002/jcsm.70076. J Cachexia Sarcopenia Muscle. 2025. PMID: 41077777 Free PMC article.
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Raimondi A, Tinè G, Ballhausen A, Lonardi S, Tougeron D, Ricagno G, Nappo F, De Vita F, Nankivell M, Cunningham D, Lee J, Kang WK, Cheong JH, Choi YY, Randon G, Prisciandaro M, Pircher CC, Manca P, Ambrosini M, Fazio R, Bergamo F, Piessen G, Smyth EC, Modest DP, Miceli R, André T, Pietrantonio F. Raimondi A, et al. Among authors: modest dp. J Clin Oncol. 2025 Nov 10;43(32):3457-3467. doi: 10.1200/JCO-25-00447. Epub 2025 Sep 29. J Clin Oncol. 2025. PMID: 41021880
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.
Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, Bergamo F, Salvatore L, Stahler A, Antoniotti C, Shitara K, Venook A, Oki E, Muro K, Ugolini C, Soeda J, Lonardi S, Pietrantonio F, Lenz HJ, Modest DP, Yoshino T, Cremolini C. Germani MM, et al. Among authors: modest dp. J Clin Oncol. 2025 Oct 10;43(29):3184-3197. doi: 10.1200/JCO-25-01003. Epub 2025 Sep 4. J Clin Oncol. 2025. PMID: 40906970 Free PMC article.
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).
Anker MS, Mahabadi AA, Totzeck M, Tewes M, Shahzeb Khan M, Mincu RI, Hendgen-Cotta UB, Michel L, Mathew B, Drescher O, Schuler M, Keller U, Rieger K, Ahn J, Bullinger L, Modest DP, Denecke C, Kretzler L, Ramer LV, Krug D, Landmesser U, Lehmann L, Frey N, Bercker S, Laufs U, Böhm M, Mahfoud F, Merkely B, Diek M, Butler J, Veiser A, Heise T, Hellmich M, Placzek M, Friede T, Anker SD, Rassaf T. Anker MS, et al. Among authors: modest dp. Eur Heart J. 2025 Aug 30:ehaf705. doi: 10.1093/eurheartj/ehaf705. Online ahead of print. Eur Heart J. 2025. PMID: 40884070
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
Ballhausen A, Morano F, Stahler A, Lonardi S, Kind AJ, Cremolini C, Swoboda S, Randon G, Horst D, Prisciandaro M, Alig AHS, Pircher CC, Jarosch A, Andena P, Kurreck A, Chiaramonte AA, Stintzing S, Pietrantonio F, Modest DP, Raimondi A. Ballhausen A, et al. Among authors: modest dp. Br J Cancer. 2025 Nov;133(9):1297-1306. doi: 10.1038/s41416-025-03164-5. Epub 2025 Aug 28. Br J Cancer. 2025. PMID: 40877636 Free PMC article. Clinical Trial.
179 results